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The well-documented viral safety of albumin arises from several factors operating in concert,
including virus removal during preparation, immune neutralization, serendipitous inactivation,
virus sterilization through pasteurization. Safety with respect to HBV transmission was achieved
evenpriortothedevelopment ofsensitivescreening tests for HBsAg, ascan bepredictedgiven the
initial virus load and the influence of factors affecting removal and inactivation. Coagulation
factor concentrates, as traditionally prepared, are known to have transmitted the viral agents of
hepatitis and AIDS with high frequency. Application of virucidal procedures to these concen-
trates, in some cases, appears to have eliminated virus transmission, raising the question as to
whether absolute safety has now been achieved. Clinical proofofabsolute safety is made difficult
by thesmall number ofeligible patients who can be monitored, lengthy and expensive monitoring
procedures, and opportunity for transmission of virus by product-independent routes. Based on
viral load analysis, modern coagulation factor concentrates are predicted to have the same
probability offreedom from HIV, HBV, and HCV transmission as that exhibited by albumin.
INTRODUCTION
A number of articles reviewing the safety of blood derivatives have appeared
recently [1-5]. For the most part, these have given an overview ofthe various methods
currently employed to inactivate viruses together with a comparison oftheir effective-
ness, based on animal and clinical study results. This paper will examine the issuefrom
a different perspective, one that is more theoretical and statistical, in which predicted
rates of infectivity ofvarious products for blood-borne viruses are calculated based on
information concerning viral loads and compared with the actual published incidence
data. By doing so, it is hoped that we will be better able tojudge whether the current
generation of coagulation factor concentrates are truly safe with regard to the
transmission of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and
hepatitis Cvirus (HCV; formerly non-A, non-B hepatitisvirus), thevirusesofprincipal
concern in blood protein derivatives.
ALBUMIN SAFETY
As a consequence of pasteurization, combined with methods of purification which
removevirus, albumin solutions have achieved an admirable record ofvirus safety [6].
The decision to prescribe and infuse albumin solutions today rests solely on issues of
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medical need and cost, and not on issues ofsafety, which is as it should be. Pasteurized
albumin is considered to be so innocuous that it is frequently used as the placebo in
clinical trials of other protein solutions, and as a fomulation aid. Understanding why
albumin is as safe as it is will place into context the new methods ofvirus inactivation
applicable to far more labile molecules than albumin.
Analysis ofvirus safety requires an appreciation ofthe initial viral load, the extent to
which virus is removed during processing, serendipitous inactivation which occurs
during processing and/or storage, the efficacy of the inactivation method employed,
and host susceptibility factors. Provided we are willing to accept a degree of uncer-
tainty, an estimate of each for HBV is provided in Table 1 for susceptible hosts
[1,7-12]. Prior to implementation ofscreening assays for HBsAg, both the proportion
of units containing infectious HBV and the titer of HBV contained in infectious units
was substantially higher than that observed today. Under this circumstance, the
probability that a vial of albumin would contain infectious HBV is calculated at 3 x
10-6. Phrased differently, one vial per 300,000 is predicted to contain infectious HBV.
This calculation is in good agreement with the occasional, but rare, outbreak of
hepatitis B arising from albumin prepared from unscreened donors. With inclusion of
HBsAg screening, the number of vials/ID50 exceeds 109. This corresponds to the
well-documented beliefthat albumin is safe [6].
While this analysis ofsafety may appear tobeesoteric, itshould beaccepted with the
same confidence as is recognized when assessing methods of bacterial sterilization,
such as by autoclaving, sterile filtration, ultraviolet irradiation, and the like. In the case
of albumin manufacture and HBV transmission, it is important to understand that
albumin's large margin of safety arises from a combination of factors operating in
concert (Fig. 1). The safety margin is sufficiently high that the U.S. Food and Drug
Administration does not generally demand a product recall following the accidental
inclusion ofplasma positive for HBsAg into a plasma pool.
SAFETY OF COAGULATION FACTOR CONCENTRATES
Traditionally Manufactured Concentrates
Coagulation factor concentrates, as traditionally prepared, transmit HIV and HCV
[6,14-16]. Based on a combination ofpublished evidence and assumptions concerning
HCV properties during fractionation, a viral load analysis similar to that provided for
albumin can be made.
The total quantity of HIV, HBV, and HCV in a plasma pool used in the manufac-
ture of a traditional AHF concentrate is estimated at 2 x 105, 3 x 105, and 4 x 107
infectiousdoses (ID50), respectively (Table 2) [3,6,14,18,20-28]. For HIV, cryoprecip-
itation and aluminum hydroxideadsorption have been reported to remove 102 ID50, and
lyophilization results in the inactivation of 101 ID50 [29]. Consequently, on filling, one
out of four vials would be expected to contain infectous HIV. A similar calculation
performed for both HBV and HCVpredicts that 30,000vials wouldcontain one ID50of
HBV and 1/0.03 vials (i.e., 40 ID50/vial) would contain infectious HCV. Based on
these estimates, a hemophiliac treated for one year with 80,000 units ofcoagulant in
theformofthese concentrates would have aprobabilityofbeingexposed toHIV, HBV,
and HCV of, respectively, 100 percent, 0.3 percent, and 100 percent. Actual transmis-
sion rates are in accord with these calculated values [6,14,15,17-19]. Of interest, as
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TABLE 1
HBV and Albumin Safety
Line 1955a 1990
1 Number ofunits/batch 24,000 24,000
2 % with HBV 0.6 0.05
3 Virus in infectious unit (ID50/mL) 1 x 106 1 x 103
4 Virus in pool (ID50) 4 x 10'0 3 x 106
5 Removal during processing 1 x lo2 1 x lo2
6 Inactivationduring processing 1 x 106 1 x 106
7 Pasteurization 1 x 104 1 X 104
8 Residual virus in pool (ID50) 4 x 10-2 3 x 10-6
9 Vials filled 12,000 12,000
10 ID50/vial 3 x 10-6 3 x 10`0
11 Vials/ID50 3 x 105 4 x 109
aPre-HBsAg screening
Line 1: A typical fractionation batch consists of6,000 litersofplasma or 24,000 units at 250mL/unit.
Line 2: HBV transmission prior to routine HBsAg testing was calculated as follows: six cases of HB
arosefrom 2,394 transfusions ofscreened,voluntarily donatedblood,indicating a perunit riskof
0.25 percent; screening had eliminated 0.12 percent oftested units [7]. This suggests a per unit
risk prior to screening of0.37 percent. Furthermore, commercially obtained blood was reported
tocarry a threefold higher hepatitis risk [35]. In a transfusion setting, ifthe ratioofvolunteer to
commercial blood was 2:1, then the overall risk from unselected, unscreened donors was 0.6
percent.
Results from thetransfusion-transmitted viral disease study in 1981 indicated that 0.27 percent
of screened, mostly voluntarily donated units were associated with HBV transmission [36].
Implementation ofmore rigorous donor selection criteria, ALTand anti-HBctesting, and donor
education have lowered HBV transmission further [21,40,48].
Line 3: The number of Dane particles in HBsAg-positive sera varies widely [10]. Almeida [37]
concluded that the sera of most chronic carriers contained about 105 Dane particles/mL.
Inclusion in a plasma pool ofan occasional infectious unit such as shown by Barker et al. [9] to
contain 1075 ID50 would raise theoverall average.
The sensitivity limit of current tests for HBsAg [38] suggests that up to 103 ID50/mL of HBV
could be in a unit which tests negative.
Line 4: Line 1 x line 2 x 250 mL/unit x line 3
Line 5: In one study [4], a 1.3 log,o removal and, in a second study [11], a 2.6 loglo removal of HBsAg
were reported. Dane particle removal may exceed the removal of HBsAg, since neither DNA
polymerase nor Dane particles weredetected in fraction V (albumin) [11].
Line 6: Anti-HBs (0.4 IU/mL) addition prevented HBV transmission to chimpanzees when added to
plasma containing approximately 5 x 104 ID50 ofHBV or to purified fractions from this plasma
[12]. An additional inactivation of 10 5 during cold ethanol fractionation is assumed.
Line 7: The inactivation ofHBV during pasteurization was shown to be limited to 104 ID50 [13].
Line 8: Line 4 . (line 5 x line 6 x line 7)
Line 9: Assumes twovials ofalbumin per liter ofplasma and 250 mL plasma per unit
Line 1O: Line 8 + line 9
Line II: 1 . line IO
compared with a hemophiliac treated with the same amount of AHF in the form of
single-donor cryoprecipitates, a hemophiliac treated with concentrate had a fourfold
higher chance ofexposure to HIV, a ninetyfold lower chance ofexposure to HBV (as a
consequence of antibody neutralization on pooling many units of plasma), and the
exposure to HCV wasvirtuallycertain foreach. Clinical experience is in linewith these
predictions [15-17].
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Modern Coagulation Factor Concentrates
Laboratory and preclinical validation ofvirucidal methods indicate a wide variance
in their effectiveness; some methods inactivate <104 ID50 of HIV, HBV, and/or HCV
(Table 3A), and other methods inactivate the highest levels of challenge available,
106-1011 ID50 for HIV, 106ID50 for HBV, and 105ID50 for HCV (Table 3B). With 200
ID50ofHIV and 0.03 ID50 ofHBV remaining in the fractionated pool (Table 2, line 7)
application of even a modestly effective virucidal procedure, e.g., one that inactivates
103 ID50, is calculated to provide rates of infectivity which approach zero. This rate
compares well with the observed transmission rates; 2/157 and 0/35 carefully moni-
tored patients were infected with HIV and HBV, respectively (Table 3A). Application
ofthe samevirucidalprocedure tothequantityofHCV estimated to be present, 40,000
ID50, is not, however, sufficient to yield an HCV-safe product. This prediction is borne
out by the observation that 29/67 ofpatients developed signs of HCV infection during
the course of several months of treatment (Table 3A). In contrast, highly virucidal
methods, defined as those shown or likely to inactivate >105 ID50 of HIV, HBV, and
HCV (Table 3B), are predicted to provide a product found to be safe in clinical
transmission studies, and such has been the case. HBV and HCV transmission has
occurred rarely and, where observed, may well represent transmission by community
vectors and not by product.
What, then, is the predicted viral safety ofmodern coagulation factor concentrates?
Adoption ofthe solvent/detergent inactivation method [30,31] or another similarly
potent virucidal procedure, when coupled with improvements in donor screening and
product purification, is calculated to increase the vials/ID50 to >1016 for HIV, >10'3
for HBV, and to >106 for HCV (Table 4). This rate compares favorably with the
predicted HBV safety ofalbumin (Fig. 2). Furthermore, it should be remembered that
the values for vials/ID50 in AHF concentrates are minimums, since, in the validation
studies, virus kill was complete to the extent ofchallenge. The potential for virus kill
can be substantially higher.
CONCLUSION
Substantial progress has been made toward eliminating virus transmission by blood
derivatives. Albumin has long been considered a virally safe product, and clinical
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TABLE 2
Viral Load ofTraditional AHF Concentrates'
Line HIV HBV HCV
I Numberofunits/batch 24,000 24,000 24,000
2 % with virus 0.04 0.05 2.00
3 Virus in infectious unit (ID50/mL) 1 x 102 1 x 102 3 x 102
4 Virus in pool (ID50) 2 x 105 3 x 105 4 x 107
5 Removalduringprocessing 1 x 102 1 x 102 1 x 102
6 Inactivationduring processing 1 x 10' 1 x 105 1 x 10l
7 Residual virus in pool (ID50) 2 x 102 3 x 10-2 4 x I04
8 Vials filled 900 900 900
9 ID50/vial 3x 10-' 3x 10-5 40
10 Vials/ID50 4 30,000 0.03
11 Annual probability ofexposure 1.0 0.003 1.00
12 Annual probability ofexposure with singledonorcryoprecipitate 0.23 0.27 1.00
aPrior to HIV and HCV antibody tests,virussterilization, andextensive purification
Line 2: HIV-Of 1,027,786 units ofdonated blood tested following licensure of HIV antibody screen-
ing, 333 were western-blot positive, or 0.038 percent [40]. In addition, it has been
estimated that from 1/40,000-1/250,000 (0.0004 percent-0.0025 percent) anti-HIV-
negativedonorbloods areinfectious for HIV [18,21,41,42].
HBV-Refer toTable 1.
HCV-Reported incidence ofhepatitis transmission with HBsAg-negative blood varies from
5.9-21 percentofrecipients [21,asummary]. On aper-unit basis, theriskvariedfrom
0.5 to 2.9 percent.
Line 3: HIV-The mean titer ofHIV in filtered plasma from asymptomatic patients and in AIDS pa-
tientswasreported tobe 10'4and 102.5TCID_0/mL, respectively [43]. In a more recent
study, HIV titers in plasma for patients with asymptomatic infections, AIDS, or ARC
were, respectively, 30, 3,500, and 3,200 TCID50/mL [251. Viral titers of infectious
plasma placed into fractionation might be higher than these values as a result of
leukocyte contamination. For asymptomatic patients, 20 per million peripheral blood
mononuclearcellshad isolatablevirus [25].
HBV-Refer toTable 1.
HCV-Chronic-phase plasma has been reported to contain infectious titers of 10'-103/mL
[28]. Acute-phaseplasma cancontain 106ID50/mL, but this has been rare [3].
Line4: Line 1 x 250 mL/unit x line 2 x line 3
Line 5: 95 percent of HIV antigen added to plasma was found in cryoprecipitate, an intermediate
fractionforAHFprocessing [44]. Aluminumhydroxide adsorptionandsubsequentpurification
by precipitation have been reported to remove/inactivate approximately 1 log each of other
retroviruses [29].
Cryoprecipitation removes 1.9log10ofHBsAg [39].
Thefractionation characteristics ofHCV areunknown at this time.
Line 6: Serendipitous inactivation during processing is uncertain. Lyophilization inactivates approxi-
mately 1 log10 of mouse retrovirus [29], and this finding is confirmed by our experience with
HIV.
Considerable HBV is neutralized by excess anti-HBs [12], found in virtually every lot offinal
product. Serendipitous inactivation ofHCV isestimated.
Line 7: Line4 -- (line 5 x line6)
Line 8: Assumes recovery of 150 U/Land 1,000U/vial
Line9: Line 7 + line 8
Line 10: 1 . line 9
Line 11: Probability ofinfection = 1 - [(1 - risk pervial) number ofvials]; assumes 80,000 units infused
peryear
Line 12: Assumes 125 units percryoprecipitate and sameassumptions asgiven for line 11
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TABLE 3A
Low Virucidal Efficacy
Clinical Safety
Validation (Log10 Kill) (Infected/Total)
Procedure HIV HBV HCV HIV HBV HCV
Heated at 600 for 30 hours as lyophilizate 2 <3.5 >3.5 2/90 0/2 2/2
Heated at 600 for 72 hours as lyophilizate -1 <2.5 endog 2/24 0/12 15/19
Heated at 680 for 72 hours as lyophilizate >2.8 NA >3.4 0/6 - 1/6
Heated at 600 for 20 hours as lyophilizate,
+ heptane >3.2 >2.7 to 4.0 2.7 to <3.5 0/37 0/18 8/37
Heated at 680 for 72 hours as lyophilizate,
+ chloroform NA NA NA 0/3 3/3
2/157 0/35 29/67
TABLE 3B
High Virucidal Efficacy
Clinical Safety
Validation (Log10 Kill) (Infected/Total)
Procedure HIV HBV HCV HIV HBV HCV
Heated at 800 for 72 hours and 800C forone
hour as lyophilizate NA NA NA 0/32 0/32 0/32
Heated at 60° for 72 hours as lyophilizate,
+ vapor >6.0 NA NA 0/109 4/53 0/58
Heated at 600 for ten hours in solution,
+ sucrose, glycine >5.0 >5.6 >5.5 0/237 2/68 2/95
Heated at 600 for 30 hours as lyophilizate, 3.0 >5.5
+ high purity >6.0 est est 0/19 - 0/19
TNBP/Detergent treated >10.0 >6.0 >5.0 0/200 0/21 0/106
>8.0 >7.0
TNBP/Detergent treated, + high purity >14.0 est est 0/45 - 0/29
Beta-Propiolactone + UV >6.0 6.9 >4.5 0/6 0/11 0/11
0/648 6/185 2/350
SeePrince et al. [3] for most references. A more recent review [51] will alsobe available.
NA, notavailable; endog, endogenous
experiencecorresponds well with predicted rates ofinfectivity based on the known viral
load and studiesquantitating virusremoval/inactivation during processing. During the
pastdecade, no fewer than 12different approaches directed toward improving theviral
safety ofcoagulation factor concentrates reached the stage where product was placed
into clinical evaluation. As a consequence, extensive information is available to permit
a good estimate of initial viral loads and of the influence of factors affecting removal
and inactivation. As shown in the accompanying analysis, there is a close correspon-
dence between clinical experience related to the transmission ofHIV, HBV, and HCV
and the predicted probability of safety, thus increasing confidence in the predictions
made. This confidence is especially important for HCV, becausedata are not available
about its fractionation characteristics and assumptions had to be made.
Thus, through the development of improved donor and donor blood screening
procedures, improved virus sterilization technology, and, in some cases, vigorous
purification methodology, the calculated margin of safety for the best of the current
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TABLE 4
Viral Load ofModern AHFConcentratesa
Line HIV HBV HCV
1 Vials/ID50 4 30,000 0.03
2 Inactivation by solvent/detergent 1 x 10l1 1 x 106 1 x i0O
3 Improveddonor select/screen 4.0 x 10' 5.0 1.5 x 10'
4 Removalduring added purification 1 x 10 1 X lox2 1 x lo2
5 Finalvials/IDm 2 x 1016 2 x 10'3 4 x 106
6 Annual probability of exposure 9 x lo-,, 5 x 10' 2 x 10-5
aFollowing HIV antibody screening, virus inactivation by solvent/detergent or other similarly potent
virucidal procedure, and immuneaffinity orother methodofextensive purification
Line 1: FromTable 2
Line 2: Piszkiewicz et al. have demonstrated the inactivation of.A0I" TCID50 of HIV on treatment by
solvent/detergent [34]. Virus kill is essentially instantaneous. In the chimpanzee model, we have
shown the inactivation of :106 CID50 of HBV and 2105 CID50 of HCV [45,46,unpublished
results].
Line 3: HIV riskdiminished asa consequenceofdonorscreening from40/100,000 to0.4-2.5 per 100,000
(see line 2, Table 2). The overall improvement in donor selection, because of public education,
donorquestionnaires, and newscreening tests must also reduce HBVviralload; fivefold is strictly
anestimate. AcombinationofALTandanti-HCVscreeningwaspredictedtodecreaseNANBHV
transmission by 60 percent [47]. When AHF is prepared from anti-HCV screened plasma, a
furtherfivefold reduction might beexpected.
HCVviral load is reduced by a combination offactors: institution ofALT and anti-HCV testing
should reduce the per-unit risk by 60 percent [47], anti-HCV testing should cause (when
performed) a reduction of 80 percent [32], and a further improvement should occur with
improvements in donor selection and adecreaseinvirus titerassociatedwith remaining infectious
units.
Line 4: Highly purified concentrates are now beginning to appear. Enhanced purification has been
reported to remove up to 10' HIV [34], though lesser removal may be seen with other viruses,
other methods, orin a production setting.
Line 5: Line 1 + (line 2 x line 3 x line4)
Line6: Assumes 80,000units infused per year
coagulation factor concentrates approaches and may exceed that calculated for
albumin. Ifcorrect, concerns ofviral risk, at least for HIV, HBV, and HCV, should no
longer hinder the clinical use of blood derivatives. This experience encourages the
preparation of virally sterilized forms of the traditional single donor products, fresh
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frozen plasma (FFP) and cryoprecipitate, even if prepared from plasma pools. With
theviral safetyofthe blood protein derivatives seemingly in hand, the final challenge in
providing safe blood products will be the development of procedures to remove or
inactivate virus from the cellular components.
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